VBC108 / VelaVigo - LARVOL DELTA

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=230 | Recruiting | Sponsor: VelaVigo Bio Inc | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=230 | Not yet recruiting | Sponsor: VelaVigo Bio Inc

First-in-human • New P1/2 trial • Oncology • Solid Tumor

VBC108: a first-in-class CDH17/CLDN18.2 targeted bispecific antibody drug conjugate (ADC) to overcome tumor heterogeneity of gastrointestinal cancers (GC, PADC, CRC, etc.) (AACR 2025) - "However, these therapies face challenges due to the heterogeneous expression of CLDN18.2, leading to inconsistent efficacy and the need of patient stratification, as observed with Zolbetuximab, AZD0901 and IBI343. VBC108 also exhibited excellent developability in a comprehensive developability assessment (DA) test, making it a strong candidate for further CMC development. In summary, VBC108, with its unique design, shows the potential as a first-in-class ADC for GI cancer and supports the advancement to clinical trials."

ADC • Bispecific • Heterogeneity • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17 • CLDN18